Standard Biotools (LAB) Debt to Equity (2021 - 2024)
Standard Biotools (LAB) has disclosed Debt to Equity for 7 consecutive years, with $0.11 as the latest value for Q3 2024.
- On a quarterly basis, Debt to Equity rose 253.74% to $0.11 in Q3 2024 year-over-year; TTM through Sep 2024 was $0.11, a 253.74% increase, with the full-year FY2023 number at -$0.39, down 289.12% from a year prior.
- Debt to Equity was $0.11 for Q3 2024 at Standard Biotools, up from $0.09 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.46 in Q1 2022 to a low of -$0.39 in Q4 2023.
- A 4-year average of -$0.03 and a median of -$0.08 in 2023 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: plummeted 289.12% in 2023, then skyrocketed 253.74% in 2024.
- Standard Biotools' Debt to Equity stood at $0.11 in 2021, then tumbled by 194.68% to -$0.1 in 2022, then tumbled by 289.12% to -$0.39 in 2023, then surged by 128.67% to $0.11 in 2024.
- Per Business Quant, the three most recent readings for LAB's Debt to Equity are $0.11 (Q3 2024), $0.09 (Q1 2024), and -$0.39 (Q4 2023).